Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials

Parents and Babies Pilot

NCT07607613
Recruiting
Conditions Perinatal Depression, Postpartum Depress...
Phase NA
Enrollment 16
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this study will be piloting the Parents and Babies perinatal depression prevention intervention to examine its feasibility and acceptability and to obtain preliminary data on its efficacy. This includes exploring/understanding users' experiences navigating the interventions (e.g., from an implementation perspective) and preliminary evaluations of clinical outcomes, including mental health and minority stress. With data gathered from this pilot study, we will make final adaptations to the Parents and Babies manuals and plan to develop a randomized-control trial to evaluate efficacy of the intervention.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: Parents and Babies Virtual Group Intervention — Parents and Babies is a 10-session intervention adapted from Mothers and Babies, a nationally recognized intervention for depression during pregnancy and postpartum built on principles of cognitive-behavioral therapy (CBT), attachment theory, and psychoeducation. Sessions are delivered virtually and led by a clinical psychologist.
  • Behavioral: Parents and Babies Hybrid Group Intervention — Parents and Babies is a 10-session intervention adapted from Mothers and Babies, a nationally recognized intervention for depression during pregnancy and postpartum built on principles of cognitive-behavioral therapy (CBT), attachment theory, and psychoeducation. Sessions are delivered virtually and led by a clinical psychologist, with an option for in-person participation at three sessions.

Primary Outcomes

  • Patient Health Questionnaire - 9 (PHQ-9) (T1 (prior to starting intervention), T2 (immediately post-intervention), T3 (3 months post-intervention))
  • Perceived Stress Scale (PSS-10) (T1 (prior to starting intervention), T2 (immediately post-intervention), T3 (3 months post-intervention))
  • Generalized Anxiety Disorder Scale (GAD-7) (T1 (prior to starting intervention), T2 (immediately post-intervention), T3 (3 months post-intervention))
  • Multidimensional Scale of Perceived Social Support (MSPSS) (T1 (prior to starting intervention), T2 (immediately post-intervention), T3 (3 months post-intervention))
  • The Acceptability of Intervention Measure (AIM) (T2 (immediately post-intervention))
  • Intervention Appropriateness Measure (IAM) (T2 (immediately post-intervention))
  • Feasibility of Intervention Measure (FIM) (T2 (immediately post-intervention))
  • Implementation of Parents and Babies skills (T2 (immediately post-intervention), T3 (3-months post-intervention))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-08-03
Completion: 2027-04
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 16 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Northwestern University
Collaborators: National Institute on Minority Health and Health Disparities (NIMHD)
Contact Information
Study Contact:
Leiszle Lapping-Carr
312- 503-3814
parentsandbabies@northwestern.edu
Northwestern University
Interventions
  • Behavioral: Parents and Babies Virtual Group Intervention — Parents and Babies is a 10-session intervention adapted from Mothers and Babies, a nationally recognized intervention for depression during pregnancy and postpartum built on principles of cognitive-behavioral therapy (CBT), attachment theory, and psychoeducation. Sessions are delivered virtually and led by a clinical psychologist.
  • Behavioral: Parents and Babies Hybrid Group Intervention — Parents and Babies is a 10-session intervention adapted from Mothers and Babies, a nationally recognized intervention for depression during pregnancy and postpartum built on principles of cognitive-behavioral therapy (CBT), attachment theory, and psychoeducation. Sessions are delivered virtually and led by a clinical psychologist, with an option for in-person participation at three sessions.
Study Locations (1 sites)
Northwestern University, Chicago, Illinois 60611 United States
Eligibility Criteria
Inclusion Criteria: * self-identify as LGBTQ+ * 18 years old or older * live in the USA or territories * speak and understand English * Currently pregnant or within one year of childbirth * Endorse current mild depressive symptoms or risk factors for postpartum depression Exclusion Criteria: * Are unable to consent/have impaired decision making capacity * Have current active suicidal or homicidal ideation, active psychosis, or current mania * Are currently experiencing a severe depressive episode * Do not have audio and/or video capacity for attending group sessions remotely.
Conditions Type 2 Diabetes, Diabetes Mellitus Type ...
Phase NA
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

AIM-MET is a randomized clinical study testing whether a fixed microbiome-targeted nutritional product can improve blood sugar control in adults with type 2 diabetes when used in addition to usual stable diabetes treatment. The study will compare the active nutritional product with a matching placebo over 24 weeks. The product was designed using artificial intelligence before the study began, but the same fixed formulation will be used for all participants assigned to the active group. Artificial intelligence will not be used during the study to make individual treatment decisions, adjust dosing, or personalize the product. The main question is whether participants receiving the active product have a greater reduction in HbA1c, a standard marker of average blood sugar levels, from the start of the study to Week 24 compared with participants receiving placebo. The study will also evaluate early blood sugar changes, fasting glucose, body weight and waist measurements in participants with baseline BMI of at least 25.0 kg/m2, safety, hypoglycaemia events, patient-reported outcomes, and gut microbiome features. This is a 100-participant proof-of-concept study intended to estimate the size of the treatment signal, safety, feasibility, and parameters needed for a future larger confirmatory trial.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Quadruple

Interventions / Regimen

  • Dietary Supplement: Microbiome-targeted oral food supplement — Fixed AI-guided microbiome-targeted oral food supplement administered for 24 weeks. The formulation is fixed and identical for all participants randomized to the active intervention arm. The artificial intelligence methodology was used before the trial for formulation design only and is not used during the trial for participant-level prediction, dosing, clinical decision-making, or formulation adjustment. Participants also receive identical structured lifestyle counselling and continue stable permitted background glucose-lowering therapy as clinically appropriate.
  • Dietary Supplement: Matching placebo oral supplement — Matching placebo oral supplement administered for 24 weeks. The placebo is matched to the active product in appearance, taste, smell, packaging, administration schedule, and storage conditions. The placebo is intended to be microbiome- and glycaemia-neutral and free of active prebiotic, probiotic, synbiotic, postbiotic, glycaemically active, or other bioactive components reasonably expected to affect HbA1c, fasting plasma glucose, body weight, microbiome composition, or inflammatory markers. Participants also receive identical structured lifestyle counselling and continue stable permitted background glucose-lowering therapy as clinically appropriate.

Primary Outcomes

  • Change in HbA1c from baseline to Week 24 (Baseline to Week 24)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-06-01
Completion: 2027-06-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: ENBIOSIS BIOTECHNOLOGIES
Collaborators: Bakırçay University, Faculty of Medicine, Aydin Adnan Menderes University, Buca Seyfi Demirsoy State Hospital, Izmir University of Economics
Principal Investigators:
  • Engin Güney, Prof. Dr. (STUDY_CHAIR) - Aydın Adnan Menderes University Faculty of Medicine Endocrinology Department
  • Varol Tunali, Dr. (PRINCIPAL_INVESTIGATOR) - Enbiosis Biotechnology Limited
Contact Information
Study Contact:
Varol TUNALI, Dr.
+905556303231
vtunali@enbiosis.com
Buğra Yağmur, Mr
+90 505 632 82 82
byagmur@enbiosis.com
Sedat Güney, Dr.
+90 554 844 92 66
sedat.guney@cbu.edu.tr
Bakırçay University Faculty of Medicine Endocrinology Department
Interventions
  • Dietary Supplement: Microbiome-targeted oral food supplement — Fixed AI-guided microbiome-targeted oral food supplement administered for 24 weeks. The formulation is fixed and identical for all participants randomized to the active intervention arm. The artificial intelligence methodology was used before the trial for formulation design only and is not used during the trial for participant-level prediction, dosing, clinical decision-making, or formulation adjustment. Participants also receive identical structured lifestyle counselling and continue stable permitted background glucose-lowering therapy as clinically appropriate.
  • Dietary Supplement: Matching placebo oral supplement — Matching placebo oral supplement administered for 24 weeks. The placebo is matched to the active product in appearance, taste, smell, packaging, administration schedule, and storage conditions. The placebo is intended to be microbiome- and glycaemia-neutral and free of active prebiotic, probiotic, synbiotic, postbiotic, glycaemically active, or other bioactive components reasonably expected to affect HbA1c, fasting plasma glucose, body weight, microbiome composition, or inflammatory markers. Participants also receive identical structured lifestyle counselling and continue stable permitted background glucose-lowering therapy as clinically appropriate.
Study Locations (1 sites)
Bakırçay University Faculty of Medicine Endocrinology Department, Izmir, Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: Adults aged 18 to 65 years. Established diagnosis of type 2 diabetes mellitus documented in the medical record, supported by American Diabetes Association diagnostic criteria on at least one prior occasion. HbA1c 6.8% to 8.2% at screening, measured by an NGSP-certified central laboratory assay; confirmed on a repeat sample if discordant with prior records or if the screening value is at the upper or lower boundary. Body mass index 18.5 to 40.0 kg/m2 at screening. Stable background glucose-lowering therapy for at least 3 months before randomization, restricted to metformin, a DPP-4 inhibitor, and/or an SGLT2 inhibitor, either alone or in combination. Documented body-weight stability, defined as no more than +/-5% or +/-3 kg, whichever is smaller, self-reported body-weight change during the 3 months before screening. Willing and able to provide written informed consent. Willing and able to comply with trial visits, study product use, fasting blood sampling, stool sampling, and the study assessment schedule. Willing to receive standardized lifestyle counselling during the 24-week blinded period and to maintain stable background diabetes management as clinically directed. No systemic antibiotic use within 8 weeks before randomization. No probiotic, prebiotic, synbiotic, or postbiotic supplement use within 8 weeks before randomization. Stable hypertension, dyslipidaemia, and stable thyroid replacement therapy are permitted if medication has been initiated and the dose unchanged for at least 3 months before randomization. Exclusion Criteria: Type 1 diabetes, latent autoimmune diabetes of adults, pancreatogenic diabetes, maturity-onset diabetes of the young, gestational diabetes as the current diagnosis, or any non-type-2 form of diabetes. HbA1c less than 6.8% or greater than 8.2% at screening. Current use of GLP-1 receptor agonists or GLP-1/GIP co-agonists, or use within 12 months before randomization. Current use of basal, prandial, or premixed insulin, or any insulin use within 6 months before randomization. Current use of sulfonylureas or meglitinides, or use within 3 months before randomization. Current use of anti-obesity pharmacotherapy or use within 6 months before randomization, including orlistat, naltrexone/bupropion, phentermine/topiramate, or other agents with a primary anti-obesity indication. Recurrent severe hypoglycaemia or hypoglycaemia unawareness. Planned initiation or dose escalation of glucose-lowering medication, anti-obesity medication, or systemic corticosteroids during the 24-week trial period in the judgment of the treating clinician. History of bariatric surgery at any time. Gastrointestinal surgery other than appendectomy or uncomplicated cholecystectomy. Active inflammatory bowel disease, coeliac disease, microscopic colitis, chronic pancreatitis, malabsorption syndrome, or chronic severe gastrointestinal disease likely to affect absorption or trial adherence. Acute gastroenteritis within 4 weeks before randomization. Colonoscopy bowel preparation within 12 weeks before randomization. Faecal microbiota transplantation within 12 months before randomization. Active or recent malignancy within 6 months, except adequately treated non-melanoma skin cancer. Stage 3b to 5 chronic kidney disease, defined as estimated glomerular filtration rate less than 45 mL/min/1.73 m2. Decompensated liver disease or Child-Pugh class B/C. ALT or AST greater than 3 times the upper limit of normal at screening, unless judged clinically insignificant and approved by the investigator. Known or suspected haemoglobinopathy that materially distorts HbA1c measurement or haemoglobin variant known to interfere with the central laboratory assay. Blood transfusion, significant blood loss greater than 250 mL, or erythropoiesis-stimulating agent therapy within 3 months before randomization. Untreated overt thyroid disease, or thyroid medication initiation or dose change within 3 months before randomization. Use of systemic corticosteroids within 4 weeks before randomization. Use of immunosuppressive medication or biologic/immunomodulatory therapy within 5 half-lives before randomization. Pregnancy or lactation; women of childbearing potential not willing to use effective contraception during the 24-week blinded period. Severe psychiatric illness or cognitive impairment that may compromise informed consent, safety, or adherence. Active eating disorder, defined operationally as a positive SCOFF screen with at least 2 affirmative responses at screening, or clinical diagnosis of anorexia nervosa, bulimia nervosa, or binge-eating disorder. Heavy alcohol use or active substance use disorder. Current very-low-calorie diet, ketogenic diet, medically supervised weight-loss diet, or other highly restrictive diet that excludes major food groups. Current cigarette smoking with intention to attempt cessation during the 24-week trial period; current users of nicotine-replacement or smoking-cessation pharmacotherapy initiated within 3 months before randomization. Participation in another interventional clinical trial within 30 days before screening. Known hypersensitivity or clinically significant intolerance to any component of the active product or placebo. Inability or unwillingness to provide stool samples. Any condition that, in the investigator's opinion, would compromise participant safety or trial integrity.
Conditions Anxiety, Stroke, Depression - Major Depr...
Phase NA
Enrollment 10
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to pilot "Maya," a mobile cognitive behavioral therapy app, for use in adults with stroke experiencing depression and/or anxiety. This study will assess the acceptability, feasibility, and preliminary efficacy of Maya within the acute rehabilitation period.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Mobile Cognitive Behavioral Therapy App — A mobile cognitive behavioral therapy (CBT) app called "Maya" that includes modules with educational content and teaching and practice of strategies that address depression and anxiety after stroke.

Primary Outcomes

  • Feasibility and Acceptability of Maya as measured by the Mobile Application Rating Scale-User Version (uMARS) (Week 5 of treatment)
  • Percent of Sessions completed over study time period (From Week 1 to Week 5 of treatment)
  • Percent of homework exercises completed (From Week 1 to Week 5 of treatment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-11
Completion: 2029-03
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 10 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Weill Medical College of Cornell University
Principal Investigators:
  • Abhishek Jaywant, PhD (PRINCIPAL_INVESTIGATOR) - Weill Medical College of Cornell University
Contact Information
Study Contact:
Abhishek Jaywant, PhD
212-746-4666
abj2006@med.cornell.edu
Abhishek Jaywant, PhD
212-746-4666
abj2006@med.cornell.edu
Weill Cornell Medicine
Interventions
  • Device: Mobile Cognitive Behavioral Therapy App — A mobile cognitive behavioral therapy (CBT) app called "Maya" that includes modules with educational content and teaching and practice of strategies that address depression and anxiety after stroke.
Study Locations (1 sites)
Weill Cornell Medicine, New York, New York 10065 United States
Eligibility Criteria
Inclusion Criteria: * Age 18-79 * Positive screen on the Hospital Anxiety and Depression Scale (HADS), either the HADSD (depression, score \>= 8) and/or HADS-A (anxiety, score \>= 8). * Stroke that occurred within 1 month prior to study initiation. * Capacity to provide consent as determined by the UCSD Brief Assessment for Capacity to Consent (UBACC) * Montreal Cognitive Assessment (MoCA) score greater than or equal to 18, indicating no more than mild cognitive difficulties * Ability to use iPhone or iPad independently or through the assistance of a caregiver (participants will use their own iPhone if they have one, otherwise they will be loaned an iPad by the study team) * Able to adhere to all study requirements and willingness to participate in the full study duration Exclusion Criteria: * Aphasia or neglect that would interfere with use of the app, as determined through evaluation by speech-language pathology and occupational therapy conducted as part of standard clinical care * Non-fluency in English * History of a major neurologic disorder or of serious mental illness (bipolar or psychotic disorder, alcohol or substance use disorder as assessed through chart review) * Active suicidal ideation requiring a higher level of care * Severe depression and/or anxiety based on the initial evaluation and clinical judgment of the PI, which warrants a higher level of care and/or immediate referral to psychiatric services * Any other clinical or medical reason in the initial evaluation that suggests the study is not appropriate for the participant
Conditions Caregiver Burden, Stress, Depression, An...
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to evaluate the preliminary efficacy, feasibility, acceptability, and barriers and facilitators to implementation of the Confident Caregiver intervention among family caregivers of persons with cardiovascular disease participating in cardiac rehabilitation. Caregivers receive four individualized intervention sessions focused on assessment of caregiving challenges, tailored coaching, stress reduction, education, and referrals to supportive resources. Outcomes include reductions in caregiving-related challenges, improvements in mental health, and reductions in stress.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Behavioral: Confident Caregiver Intervention — All enrolled caregivers receive the Confident Caregiver intervention. No comparison group is included.

Primary Outcomes

  • Level of Caregiving Difficulty Scale - developed by Gitlin et al and previously used in the COPE trial (Care of Persons With Dementia in Their Environments). Range 1-10, higher scores indicate greater caregiving difficulty. (From baseline to immediately following completion of the Confident Caregiver intervention)
  • Level of Caregiving Upset Scale - developed by Gitlin et al and previously used in the COPE trial. Range 1-10, higher scores indicate greater caregiving-related upset. (From baseline to immediately following completion of the Confident Caregiver intervention)
  • Level of Caregiving Confidence Scale - developed by Gitlin et al and previously used in the COPE trial. Range 1-10, higher scores indicate greater caregiving confidence. (From baseline to immediately following completion of the Confident Caregiver intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-07-23
Completion: 2027-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of California, Davis
Collaborators: Gordon and Betty Moore Foundation
Contact Information
Study Contact:
Julie T Bidwell, PhD,RN
503-756-1996
jtbidwell@health.ucdavis.edu
Julie T Bidwell, PhD, RN
503-756-1996
jtbidwell@health.ucdavis.edu
University of California Davis Health System
Interventions
  • Behavioral: Confident Caregiver Intervention — All enrolled caregivers receive the Confident Caregiver intervention. No comparison group is included.
Study Locations (1 sites)
University of California Davis Health System, Sacramento, California 95817 United States
Eligibility Criteria
Inclusion Criteria: * 18 years of age or older * Is a caregiver for a patient receiving care in our UC Davis Cardiac Rehabilitation Clinic. A caregiver is defined as someone who provides support to the patient with one or more basic or instrumental activities of daily living. * Has one or more caregiving-related challenges or issues that they would like support with * Is able to read and speak in English Exclusion Criteria: * Is a paid professional caregiver with no family or fictive kin relationship with the care recipient * Has a diagnosis of major cognitive impairment or Alzheimer's or related dementias * Is unable to complete the protocol or participate in the intervention (e.g., unavailable during the intervention period, unable to access or use virtual meeting technology)
Conditions Obesity Type 2 Diabetes Mellitus
Phase NA
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study is designed to evaluate the efficacy, safety, and mechanisms of combining ESG and pulsENDO procedure in obese patients with T2DM

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: Endoscopic sleeve gastroplasty plus duodenal recellularization via electroporation therapy (pulsENDO) — First part - pulsENDO procedure : The pulsENDO procedure utilizes the pulsENDO catheter to deliver non-thermal pulsed electric field to the duodenum to induce cell regeneration. The catheter is introduced to the duodenum through the mouth using a guide wire and the therapy is applied to treat the duodenum under endoscopic visualisation, starting from D4 and repeated proximally. Approximately 10-18 cm of axial length of the duodenum is treated. Second part - Endoscopic sleeve gastroplasty : ESG is performed using an endoscopic suturing device (Overstitch, BSC) to reduce the stomach volume through the creation of a restrictive endoscopic sleeve. This is accomplished with around 4-7 permanent full thickness sutures over greater curve stomach in a running plication extending from the angular incisura and continuing proximally with fundal sparing.

Primary Outcomes

  • Change in Diabetic medications (12 months post-procedure)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-09-01
Completion: 2031-07-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Chinese University of Hong Kong
Principal Investigators:
  • Stephen Ng (PRINCIPAL_INVESTIGATOR) - Prince of Wales Hospital, the Chinese University of Hong Kong
Contact Information
Study Contact:
Stephen Ng
+85235052956
stephenng@surgery.cuhk.edu.hk
Ivy Study coordinator
+85235052956
ivypoon@surgery.cuhk.edu.hk
Stephen Ng, FRCSEd(Gen)
+85235052956
stephenng@surgery.cuhk.edu.hk
Prince of Wales Hospital, the Chinese University of Hong Kong
Interventions
  • Procedure: Endoscopic sleeve gastroplasty plus duodenal recellularization via electroporation therapy (pulsENDO) — First part - pulsENDO procedure : The pulsENDO procedure utilizes the pulsENDO catheter to deliver non-thermal pulsed electric field to the duodenum to induce cell regeneration. The catheter is introduced to the duodenum through the mouth using a guide wire and the therapy is applied to treat the duodenum under endoscopic visualisation, starting from D4 and repeated proximally. Approximately 10-18 cm of axial length of the duodenum is treated. Second part - Endoscopic sleeve gastroplasty : ESG is performed using an endoscopic suturing device (Overstitch, BSC) to reduce the stomach volume through the creation of a restrictive endoscopic sleeve. This is accomplished with around 4-7 permanent full thickness sutures over greater curve stomach in a running plication extending from the angular incisura and continuing proximally with fundal sparing.
Study Locations (1 sites)
Prince of Wales Hospital, the Chinese University of Hong Kong, Shatin, Hong Kong
Eligibility Criteria
Inclusion Criteria: * BMI \>/= 27kg/m2 * Known T2DM * Individualized Metabolic Surgery (IMS) score 25-115 * HbA1c \<11% (subjects on oral glucose lowering drug(s) or HbA1c \<8% (subjects on insulin) Exclusion Criteria: * Previous treatment with ReCET, ESG or similar procedure * Previous GI surgery that could preclude the ability to perform ReCET or ESG, or acute gastric and duodenal pathology that increased the risk of ReCET or ESG * Type 1 DM, DM secondary to specific disease or having any history of ketoacidosis * Fasting C-peptide level \<0.5ug/L * Any inflammatory disease of the gastrointestinal tract such as Crohn's disease * Abnormal pathologies or conditions of the gastrointestinal tract, including duodenal polyps, ulcers or upper gastrointestinal bleeding conditions within 3 months of study * Uncorrectable bleeding diathesis, platelet dysfunction, thrombocytopenia with platelet count less than 100,000/microliter or known coagulopathy * Currently taking prescription antithrombotic therapy (e.g., anticoagulant agent) within 10 days prior to study and/or there is a need or expected need to use during the study period * Currently taking medications known to cause significant weight gain or weight loss (e.g. chemotherapeutics) * Patients who have used non-steroidal analgesics and anti-inflammatory drugs (NSAID) and corticosteroids in the past 1 month * Underlying uncontrolled endocrine problem that leads to obesity, including and not limited to hypothyroidism, Cushing syndrome and eating disorder. * Patients with contra-indications to endoscopy * Patients with cirrhosis due to causes other than MASLD * Malignancy * Diagnosis of autoimmune connective tissue disorder (e.g. lupus erythematosus, scleroderma) * Pregnant or breast feeding * ASA grade IV \& V * Mental or psychiatric disorder; Drug or alcohol addiction * Other cases deemed by the examining physician as unsuitable for safe treatment * Refusal to participate
Conditions Breast Cancer, Chemotherapy-induced Diar...
Phase PHASE2
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to evaluate whether the addition of probiotics can help reduce abdominal discomfort (such as diarrhea) in breast cancer patients receiving Abemaciclib treatment. Abemaciclib is an effective targeted therapy but often causes gastrointestinal side effects. While Loperamide is the standard treatment for diarrhea, this study explores if probiotics can provide additional relief and improve metabolic health.Participants will be randomly assigned to receive either probiotics or a placebo alongside their standard care. The study will monitor the frequency of abdominal symptoms and analyze blood samples to observe changes in metabolic factors.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Crossover Primary purpose: Supportive Care Masking/blinding: Quadruple

Interventions / Regimen

  • Dietary Supplement: Synbiotic supplement followed by Placebo — The synbiotic supplement contains Bifidobacterium longum (probiotics), Oligonol® lychee polyphenol (prebiotics), and functional postbiotics. Participants will take two capsules daily for 2 months during the assigned study phase. This intervention is administered orally to evaluate its efficacy in alleviating Abemaciclib-induced abdominal discomfort.
  • Dietary Supplement: Placebo followed by Probiotics — Participants in this sequence will receive the placebo for the first 2 months, followed by a 2-month period of receiving the synbiotic supplement (containing Bifidobacterium longum, lychee polyphenol, and postbiotics). All participants continue their prescribed Abemaciclib and endocrine therapy. Standard anti-diarrhea medication (Loperamide) is available as needed.

Primary Outcomes

  • Incidence of Grade 2 or Higher Diarrhea (During the first 2 months of the intervention.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-05-15
Completion: 2029-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Leeuwenhoek Laboratories Co. Ltd.
Contact Information
Study Contact:
Chiao-Wei Lin
+886-2-2377-2318
cwlin@lwhklab.com.tw
Wei-Li Ma
+886-2-2312-3456
excellent0667@gmail.com
National Taiwan University Hospital
Interventions
  • Dietary Supplement: Synbiotic supplement followed by Placebo — The synbiotic supplement contains Bifidobacterium longum (probiotics), Oligonol® lychee polyphenol (prebiotics), and functional postbiotics. Participants will take two capsules daily for 2 months during the assigned study phase. This intervention is administered orally to evaluate its efficacy in alleviating Abemaciclib-induced abdominal discomfort.
  • Dietary Supplement: Placebo followed by Probiotics — Participants in this sequence will receive the placebo for the first 2 months, followed by a 2-month period of receiving the synbiotic supplement (containing Bifidobacterium longum, lychee polyphenol, and postbiotics). All participants continue their prescribed Abemaciclib and endocrine therapy. Standard anti-diarrhea medication (Loperamide) is available as needed.
Study Locations (1 sites)
National Taiwan University Hospital, Taipei, Taiwan
Eligibility Criteria
Inclusion Criteria: A. Adults with hormone receptor-positive (HR+) early breast cancer were confirmed. B. At least 18 years old at the time of signing the informed consent. C. Candidates for adjuvant endocrine therapy in combination with Abemaciclib (either NHI-reimbursed or self-funded), as determined by the primary treating physician. Prior chemotherapy requirement: Must have completed prior adjuvant chemotherapy at least 21 days before enrollment. All chemotherapy-related toxicities (except alopecia or Grade 2 peripheral neuropathy) must have resolved to ≤ Grade 1. D. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. E. Adequate bone marrow function as defined by: 1. Absolute Neutrophil Count (ANC) ≥ 1,500/μL without G-CSF support within 14 days of enrollment. 2. Platelet count ≥ 100,000/μL. 3. Hemoglobin ≥ 8.0 g/dL (red blood cell transfusion is permitted prior to enrollment). F. Adequate hepatic function, as defined by: 1. Serum alkaline phosphatase (ALP), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) ≤ 3× the upper limit of normal. 2. Total bilirubin (T-bil) ≤ 1.5× the upper limit of normal. G. Willingness to refrain from using any other oral probiotics or prebiotics from the first dose of the study intervention ("Synbiotic Supplement" or placebo) through study completion. H. Ability to communicate with study personnel and willingness to comply with study visits, treatment plans, and other trial regulations. Exclusion Criteria: A. Currently pregnant or breastfeeding. B. Received systemic antibiotic therapy for active viral, bacterial, or fungal infections within 2 weeks before the first dose of the study intervention. C. Severe pre-existing medical conditions that, in the investigator's judgment, preclude participation, including but not limited to the following: 1. Severe renal impairment (e.g., estimated creatinine clearance \< 30 mL/min). 2. Interstitial lung disease. 3. Severe dyspnea at rest or the requirement for oxygen therapy. 4. History of major gastrointestinal surgeries, such as gastrectomy or small bowel resection. 5. Pre-existing Crohn's disease, ulcerative colitis, or other chronic conditions that cause clinically significant diarrhea. D. History of the following cardiovascular conditions: syncope of cardiovascular origin, ventricular arrhythmias of pathological origin (including ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest. Exception: Patients with atrial fibrillation that is controlled and stable for at least 30 days before randomization are eligible. E. Unwillingness or inability to provide written informed consent.
Conditions Depressive Disorder, Treatment-Resistant
Phase PHASE3
Enrollment 348
Locations 22 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to evaluate how well each individual dose of esketamine (56 milligrams \[mg\] and 84 mg) works when compared with placebo in improving depressive symptoms in participants with treatment resistant depression (individuals with major depressive disorder \[MDD\] who have not responded to at least 2 different antidepressant treatments given at an adequate dose for an adequate duration in the current episode of depression).

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: Esketamine 56 mg — Participants will self-administer 56 mg of esketamine as intranasal spray into each nostril.
  • Drug: Esketamine 84 mg — Participants will self-administer 84 mg of esketamine as intranasal spray into each nostril.
  • Drug: Placebo — Participants will self-administer placebo as intranasal spray into each nostril.

Primary Outcomes

  • Double-Blind (DB) Treatment Phase: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Day 1 to the End of the 4-Week Double-Blind Treatment Phase (Baseline (Day 1 [prerandomization]) up to end of the 4-Week DB treatment phase (Day 28))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2026-07-23
Completion: 2029-09-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 348 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Janssen Research & Development, LLC
Principal Investigators:
  • Janssen Research & Development, LLC Clinical Trial (STUDY_DIRECTOR) - Janssen Research & Development, LLC
Contact Information
Study Contact:
Study Contact
844-434-4210
Participate-In-This-Study1@its.jnj.com
Interventions
  • Drug: Esketamine 56 mg — Participants will self-administer 56 mg of esketamine as intranasal spray into each nostril.
  • Drug: Esketamine 84 mg — Participants will self-administer 84 mg of esketamine as intranasal spray into each nostril.
  • Drug: Placebo — Participants will self-administer placebo as intranasal spray into each nostril.
Study Locations (22 sites)
Anderson Clinical Research, Redlands, California 92374 United States
Artemis Institute for Clinical Research, San Diego, California 92123 United States
Psych Atlanta, P.C., Marietta, Georgia 30060 United States
Psychiatric Medicine Associates LLC, Skokie, Illinois 60076 United States
Neurobehavioral Research Inc, Cedarhurst, New York 11516 United States
The Medical Research Network, LLC, New York, New York 10128 United States
Northwest Clinical Research Center, Bellevue, Washington 98007 United States
Kishiro Mental Clinic, Kawasaki, 214-0014 Japan
Tatsuta Clinic, Kobe, 651-0097 Japan
National Center of Neurology and Psychiatry, Kodaira-shi, 187-8551 Japan
Eligibility Criteria
Inclusion Criteria: * Participant must meet the diagnostic and statistical manual of mental disorders (5th edition) (DSM-5) diagnostic criteria for single-episode major depressive disorder (MDD) (if single episode MDD, the duration of the episode must be greater than or equal to \[\>=\] 12 months) or recurrent MDD, without psychotic features, based upon clinical assessment and confirmed by the mini international neuropsychiatric interview (MINI) as the primary diagnosis. Participant must have had the first onset of depression prior to 55 years of age * Participant must have had nonresponse (less than or equal to \[\<=\] 25 percent \[%\] improvement) to \>=2 oral antidepressant treatments in the current episode of depression, assessed using the massachusetts general hospital-antidepressant treatment response questionnaire (MGH-ATRQ), and confirmed by documented records (for example, medical/pharmacy/prescription records or a letter from a treating physician) * The participant's current major depressive episode, depression symptom severity, and antidepressant treatment response in the current depressive episode, must be confirmed by the state versus trait, assessability, face validity, ecological validity, rule of three P's (SAFER) Interview * Participant must be comfortable with self-administration of nasal spray medication and be able to follow the nasal spray administration instructions provided * A female participant of childbearing potential must have a negative highly sensitive serum (β-human chorionic gonadotropin \[β-hCG\]) at the start of screening and a negative urine pregnancy test must be obtained before the first dose of study drug on Day 1, prior to randomization Exclusion Criteria: * The participant has used ketamine/esketamine (lifetime) * The participant's depressive symptoms have demonstrated nonresponse in the current major depressive episode to an adequate course of treatment with electroconvulsive therapy (ECT), defined as at least 7 treatments with unilateral/bilateral ECT, or to adequate course of treatment with transcranial magnetic stimulation (TMS), defined as at least 4 weeks of treatment with 5 sessions per week * Participant has received vagal nerve stimulation (VNS) or deep brain stimulation (DBS) in the current episode of depression * Participant has homicidal ideation/intent, per the investigator's clinical judgment, or has suicidal ideation with some intent to act within 6 months prior to the start of the screening phase, per the investigator's clinical judgment or based on the columbia suicide severity rating scale (C-SSRS), corresponding to a response of "Yes" on Item 4 (active suicidal ideation with some intent to act, without specific plan) or Item 5 (active suicidal ideation with specific plan and intent) for suicidal ideation on the C-SSRS, or a history of suicidal behavior within the past year prior to the start of the screening phase. Participants reporting suicidal ideation with intent to act or suicidal behavior prior to the start of the double-blind treatment phase should be excluded * Participant has a history of moderate or severe substance or alcohol use disorder according to DSM-5 criteria, except nicotine or caffeine, within 6 months before the start of the screening phase. a. A history (lifetime) of ketamine, phencyclidine (PCP), lysergic acid diethylamide (LSD), or 3, 4-methylenedioxy-methamphetamine (MDMA) hallucinogen-related use disorder is exclusionary * Participant has a current or history of seizures (uncomplicated childhood febrile seizures with no sequelae are not exclusionary)
Conditions Breast Cancer
Phase NA
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a prospective pilot study of breast cancer patients undergoing axillary lymph node dissection (ALND) or sentinel lymph node biopsy (SLNB). Participants will undergo ultra-high frequency ultrasound (UHFUS) imaging with indocyanine green (ICG) dye to map lymphatic channels between the wrist and elbow to investigate normal lymphatic anatomy in patients with breast cancer.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Procedure: Indocyanine green (ICG) solution injection — 0.1cc of 2.5 mg/cc Indocyanine green (ICG) solution will be injected intradermally at the 1st and 4th webspaces of the hand, and radial and ulnar volar wrist areas.
  • Device: Ultra-High Frequency Ultrasound — UHFUS will capture still images at specific landmarks along the wrist-to-elbow axis to characterize lymphatic channels. The following quantitative data of lymphatic channels will be captured: 1\. Outer diameter (i.e., total diameter including wall and lumen); 2. Inner diameter (i.e., diameter of the lumen only); and 3. Wall thickness (i.e., the thickness of the lymphatic channel wall)

Primary Outcomes

  • Outer lymphatic vessel diameter (During ultra-high frequency ultrasound imaging)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-06-17
Completion: 2036-09-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of California, Davis
Contact Information
Study Contact:
Sheri Nichols
(916) 734-7289
slnichols@health.ucdavis.edu
Shari Nichols
(916) 734-7289
slnichols@health.ucdavis.edu
University of California Davis Health
Ara Salibian, MD
University of California Davis Health
Interventions
  • Procedure: Indocyanine green (ICG) solution injection — 0.1cc of 2.5 mg/cc Indocyanine green (ICG) solution will be injected intradermally at the 1st and 4th webspaces of the hand, and radial and ulnar volar wrist areas.
  • Device: Ultra-High Frequency Ultrasound — UHFUS will capture still images at specific landmarks along the wrist-to-elbow axis to characterize lymphatic channels. The following quantitative data of lymphatic channels will be captured: 1\. Outer diameter (i.e., total diameter including wall and lumen); 2. Inner diameter (i.e., diameter of the lumen only); and 3. Wall thickness (i.e., the thickness of the lymphatic channel wall)
Study Locations (1 sites)
University of California Davis Health, Sacramento, California 95816 United States
Eligibility Criteria
Inclusion Criteria: * 1\. Aged 18+ at the time of consent. * 2\. Confirmed breast cancer diagnosis * 3\. Planned ALND (CPT code: 38745) or SLNB (CPT code: 38900) for breast cancer treatment * 4\. Provision of a signed and dated informed consent form. * 5\. Stated willingness to comply with all study procedures and availability for the duration of the study. Exclusion Criteria: * 1\. History of transient or permanent edema of the extremity, including edema ≥stage 1 per the International Society of Lymphology (ISL) staging system 15 * 2\. History of prior axillary nodal surgery * 3\. History of any lymphatic disease or venous disease of the upper extremity, including deep venous thrombosis
Conditions Depression, Parkinson's Disease (PD)
Phase PHASE2
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to understand whether people with Parkinson's Disease and depression have improvement in their symptoms after psilocybin therapy.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Psilocybin (drug) — Single dose of psilocybin ranging from low ("microdose") to high delivered orally with psychological support and monitoring
  • Drug: Psilocybin (drug) — Single dose of psilocybin ranging from low ("microdose") to high delivered orally with psychological support and monitoring

Primary Outcomes

  • Change in depression as measured by the Montgomery-Asberg Depression Rating Scale (MADRS) (Baseline to 30 days after first drug dose)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-07
Completion: 2030-07
Eligibility
Age: 40 Years and older
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Yale University
Collaborators: Michael J. Fox Foundation for Parkinson's Research
Principal Investigators:
  • Sophie Holmes, PhD (PRINCIPAL_INVESTIGATOR) - Yale University
Contact Information
Study Contact:
Sophie Holmes, PhD
203-685-4066
sophie.holmes@yale.edu
Gerard Sanacora, MD
gerard.sanacora@yale.edu
Sophie Holmes, PhD
203-685-4066
sophie.holmes@yale.edu
Yale University
Interventions
  • Drug: Psilocybin (drug) — Single dose of psilocybin ranging from low ("microdose") to high delivered orally with psychological support and monitoring
  • Drug: Psilocybin (drug) — Single dose of psilocybin ranging from low ("microdose") to high delivered orally with psychological support and monitoring
Study Locations (1 sites)
Yale University, New Haven, Connecticut 06510 United States
Eligibility Criteria
Inclusion Criteria: * Able to understand and provide informed consent * Comfortable speaking and writing in English * Have neurologist-diagnosed idiopathic Parkinson's disease (PD), Hoehn and Yahr stages 1 to 3 during an "on" phase (time when medication/DBS for parkinsonian motor feature, including bradykinesia and rigidity is in effect) * Have no changes in medication or major surgical procedures anticipated for treatment duration * Have a score \>/=20 on the Beck Depression Inventory-2 (BDI-2), consistent with moderate or greater depressive symptom severity, at Baseline. * For people who can become pregnant: agree to use highly effective contraception from entry into the trial through Day B30 assessments (4 weeks after the second psilocybin administration session) and agree to not breastfeed. Acceptable methods of contraception are: An intrauterine device (IUD), hormone-based contraceptives (birth control pills) , condoms (internal or external) must be used with another method (other than spermicide), and complete abstinence from sexual activity that could result in pregnancy. * Agree that for one week preceding each psilocybin session, they will refrain from taking any nonprescription medication, nutritional supplement, or herbal supplement except when approved by the research team. Exceptions will be evaluated by the research team and assessed for safety. Agree to abstain from all tobacco and nicotine use for the duration of the study. * Agree to consume approximately the same amount of caffeine-containing beverages that they usually consume before arriving at the research unit on the mornings of psilocybin administration sessions. * Agree to avoid sedative-hypnotic medications (e.g., benzodiazepines, zolpidem, zopiclone, zaleplon) taken on an as-needed basis for a minimum of 5 half-lives prior to each psilocybin administration session and for 24 hours after each psilocybin administration session. * Agree to avoid opioid medications taken on an as-needed basis for a minimum of 5 half-lives prior to each psilocybin administration session and for 24 hours after each psilocybin administration session. * Agree not to use products or substances containing Δ9-tetrahydrocannabinol (THC) and/or cannabidiol for at least 7 days prior to each psilocybin administration session and for 24 hours after each psilocybin administration session. * Agree to not use non-prescribed narcotics (eg. heroine, fentanyl), depressants (eg. Barbiturates, benzodiazepines) and/or inhalants for the duration of participation in the trial. * Agree not to consume alcoholic beverages for at least 24 hours prior to and 24 hours following each psilocybin administration session. * Have a primary care provider, neurologist, or psychiatrist who is actively managing or coordinating care and is available for consultation with the study medical monitor. Exclusion Criteria: * Any indication of forms of parkinsonism other than idiopathic Parkinson's disease. * Cognitive impairment, defined as a Montreal Cognitive Assessment (MoCA) score \<24. * Symptomatic orthostatic hypotension. * Currently receiving electroconvulsive therapy (ECT) or treatment via transcranial magnetic stimulation (TMS). Previous treatment with ECT and/or TMS is permitted; last treatment must be at least 30 days prior to entry into this trial. * Treatment in a clinical trial within 30 days of entry into this trial or treatment with another investigational drug or other intervention within 30 days or 5 half-lives, whichever is longer, prior to entry into this trial. * Pregnancy as indicated by a positive urine pregnancy test during screening, lactation, or the intention of becoming pregnant within 3 months of entry into this trial. * Current severity of psychiatric symptoms warranting immediate treatment as determined by the study medical staff (e.g. due to inability to provide for basic needs/safety). The study medical staff will assess these individuals, determine the appropriate level of care, and coordinate with the individual's primary providers to ensure close follow-up. * High risk of self-harm/suicide, as determined by the Columbia-Suicide Severity Rating Scale (C-SSRS) risk screen, specifically: participant answers "yes" to item 4 or 5 suggesting intent to act on suicidal thoughts OR participant has made a serious suicide attempt within the 12 months prior to entry into this trial. * History of meeting DSM-5 criteria for a schizophrenia spectrum disorder, other psychotic disorder, or a mood disorder with psychotic features. * History of delusional symptoms or any other psychotic symptoms accompanied by a loss of insight. Exceptions may be made at the investigators' discretion in cases of a history of psychotic symptoms that were attributable to substance or medication use. * Current delusional symptoms or any other psychotic symptoms accompanied by a loss of insight. * History of a schizophrenia spectrum disorder in a first-degree relative. * History of bipolar disorder 1 in a first-degree relative, in whom illness onset was prior to age 40. * Current or history of meeting DSM-5 criteria for a bipolar disorder. * Current or history within the last 2 years of meeting DSM-5 criteria for a moderate or severe alcohol or drug use disorder, excluding caffeine. * Currently meeting DSM-5 criteria for another psychiatric condition judged to be incompatible with establishment of rapport or safe exposure to psilocybin treatment procedures as determined by the investigators. * History of meeting DSM-5 criteria for Hallucinogen Persisting Perception Disorder (HPPD). * History of using any psychedelic substances including psilocybin, lysergic acid diethylamide (LSD), mescaline (and natural products containing mescaline including peyote and San Pedro cactus), N,N-Dimethyltryptamine (DMT), natural products containing DMT including ayahuasca and 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT), ibogaine, 2C compounds, 3,4-methylenedioxy-methamphetamine (MDMA), or methylone during the past 6 months at dosages and/or frequencies determined clinically significant by the investigators. * Cancer with known central nervous system (CNS) involvement, CNS infection, or other major CNS disease aside from PD. * Epilepsy or other seizure disorder in adulthood. * Supplemental oxygen requirement. * Allergy or intolerance to any of the materials contained in the drug products. * Renal insufficiency defined as creatinine clearance \< 40 ml/min using Cockraft and Gault equation * Insufficiently managed endocrine conditions, including diabetes mellitus and clinically significant thyroid dysfunction. * Cardiovascular conditions, including: * Elevated blood pressure defined as systolic blood pressure (SBP) \>150 or diastolic blood pressure (DBP) \>95 taken during Enrollment * Tachycardia defined as heart rate (HR) \>90 beats per minute taken during Enrollment * Bradycardia defined as HR \<50 bpm taken during Enrollment * Angina * History of stroke within the past year * Clinically significant ECG abnormality as determined by the investigators, including but not limited to QTc \> 450 * Hepatic dysfunction as indicated by any of the following laboratory values: * AST \> 3 x upper limit of normal * ALT \> 3 x upper limit of normal * Total bilirubin \> 3.0 mg/dl * Use of any of the following concomitant medications AND inability/unwillingness to discontinue for at least 5 times the elimination half-life of the agent (specific exceptions are noted) prior to psilocybin administration, including: * Agents that may be associated with serotonin syndrome: * MAO inhibitors (participants must have discontinued 2 weeks prior to baseline) * St. John's Wort * S-adenosyl-methionine (SAM-e) * 5-Hydroxytryptophan (5-HTP) * Dextromethorphan * Opioids (e.g., codeine, fentanyl, hydrocodone, meperidine, tramadol) * Lithium * Linezolid * Buspirone * Agents that may interact with psilocybin metabolism/effects:
Conditions Breast Cancer
Phase PHASE2
Enrollment 70
Locations 11 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a multicenter, open-label, Phase 2 bridging study to evaluate the efficacy and safety of elacestrant in Japanese post-menopausal women and men with estrogen receptor positive (ER+)/human epidermal growth factor receptor 2 negative (HER2-) advanced or metastatic breast cancer with estrogen receptor 1 gene mutation (ESR1-mut) whose disease has relapsed or progressed on at least 1 and no more than 2 prior lines of endocrine therapy for metastatic breast cancer, which must have included cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy in combination with fulvestrant or an aromatase inhibitor.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Elacestrant — Administered as an oral tablet

Primary Outcomes

  • Progression-free Survival as Assessed by the Imaging Review Committee (Up to approximately 27 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-08-18
Completion: 2028-10
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 70 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Stemline Therapeutics, Inc.
Principal Investigators:
  • Medical Director (STUDY_DIRECTOR) - Stemline Therapeutics, Inc.
Contact Information
Study Contact:
Stemline Trials
1-877-332-7961
clinicaltrials@menarinistemline.com
Rikiya Nakamura
Chiba Cancer Center
Makoto Kubo
Kyushu University Hospital
Interventions
  • Drug: Elacestrant — Administered as an oral tablet
Study Locations (11 sites)
Chiba Cancer Center, Chiba, Japan
Kyushu University Hospital, Fukuoka, Japan
National Hospital Organization - Kyushu Medical Center, Fukuoka, Japan
Saitama Cancer Center, Ina, Japan
Tokai University Hospital, Isehara, Japan
The Cancer Institute Hospital of JFCR (Japanese Foundation For Cancer Research), Kōtō City, Japan
Kumamoto Shinto General Hospital, Kumamoto, Japan
Kumamoto University Hospital, Kumamoto, Japan
National Hospital Organization - Osaka National Hospital, Osaka, Japan
National Hospital Organization - Hokkaido Cancer Center, Sapporo, Japan
Eligibility Criteria
Key Inclusion Criteria: * Must have a histologically or cytologically proven diagnosis of adenocarcinoma of the breast with evidence of either locally advanced disease not amenable to resection or radiation therapy with curative intent or metastatic disease not amenable to curative therapy * Female participants must be post-menopausal (as defined by the protocol) * Must have ER+ and HER2- tumor status confirmed per local laboratory testing * Participants must be ESR1-mutant positive determined via testing with the Guardant360 Companion Diagnostic panel test prior to enrollment * Must have disease progression during or within 28 days of completion of prior treatment with a CDK4/6 inhibitor in combination with either fulvestrant or an aromatase inhibitor (this counts as a line of prior endocrine therapy) for metastatic breast cancer Key Exclusion Criteria: * Prior treatment with: elacestrant or investigational or approved selective estrogen receptor degrader or ER antagonist; antibody-drug conjugate therapy for advanced/metastatic breast cancer; anti-cancer or investigational drug treatment * Radiation therapy within 14 days (28 days for brain lesions) before the first dose of study drug * Intact uterus with a history of endometrial intraepithelial neoplasia (atypical endometrial hyperplasia or higher-grade lesion) * Diagnosis of any other malignancy within 5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or second primary breast cancer Note: Other protocol-defined inclusion/exclusion criteria may apply.
Conditions Perinatal Anxiety, Perinatal Depression,...
Phase NA
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Perinatal anxiety and depression are common mental health concerns that may negatively affect maternal well-being, infant development, and family functioning. Mindfulness-based interventions have shown beneficial effects on reducing psychological distress during pregnancy; however, maintaining attention and engagement during mindfulness practice may be challenging for some pregnant women. This randomized controlled trial aims to evaluate the feasibility and effectiveness of an integrated virtual forest environment and mindfulness-based intervention for improving mental health in perinatal women. Pregnant women between 20 and 24 weeks of gestation will be randomly assigned to either an experimental group receiving virtual reality (VR)-based forest mindfulness intervention or a control group receiving conventional mindfulness intervention. Both groups will participate in a 9-week mindfulness program and receive app-based mindfulness practice. The experimental group will additionally receive immersive VR forest-based mindfulness sessions during prenatal visits. Outcomes including anxiety, depression, mindfulness awareness, physiological indicators, and intervention acceptability will be assessed during pregnancy and postpartum follow-up.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: Virtual Reality Forest Mindfulness Intervention — Participants will receive immersive virtual reality-based forest mindfulness intervention combined with mindfulness-guided practice during pregnancy.
  • Behavioral: Conventional Mindfulness Intervention — Participants will receive conventional mindfulness-guided intervention during pregnancy without virtual reality exposure. The intervention includes mindfulness-guided audio focusing on breathing awareness, emotional regulation, present-moment attention, and maternal-fetal connection. Participants will additionally receive a 9-week mindfulness program and app-based mindfulness practice.

Primary Outcomes

  • Generalized Anxiety Disorder-7 (GAD-7) Score (Baseline (20-24 weeks gestation), post-intervention (32 weeks gestation to before delivery), and 1 month, 3 months, and 6 months postpartum)
  • Edinburgh Postnatal Depression Scale (EPDS) Score (Baseline (20-24 weeks gestation), post-intervention (32 weeks gestation to before delivery), and 1 month, 3 months, and 6 months postpartum)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-06-16
Completion: 2027-12-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Taiwan University Hospital
Principal Investigators:
  • HUNG-HUI CHEN, PhD (PRINCIPAL_INVESTIGATOR) - National Taiwan University Hospital
Contact Information
Study Contact:
HUNG-HUI CHEN, PhD
886-2-2394-7109
hunghuichen@ntu.edu.tw
HUNG-HUI CHEN
+886-2-23947109
hunghuichen@ntu.edu.tw
National Taiwan University Hospital Hsin-Chu Branch BioMedical Park Hospital
Interventions
  • Behavioral: Virtual Reality Forest Mindfulness Intervention — Participants will receive immersive virtual reality-based forest mindfulness intervention combined with mindfulness-guided practice during pregnancy.
  • Behavioral: Conventional Mindfulness Intervention — Participants will receive conventional mindfulness-guided intervention during pregnancy without virtual reality exposure. The intervention includes mindfulness-guided audio focusing on breathing awareness, emotional regulation, present-moment attention, and maternal-fetal connection. Participants will additionally receive a 9-week mindfulness program and app-based mindfulness practice.
Study Locations (1 sites)
National Taiwan University Hospital Hsin-Chu Branch BioMedical Park Hospital, Hsinchu, 302058 Taiwan
Eligibility Criteria
Inclusion Criteria: * Pregnant women aged 18 years or older * Gestational age below 25 weeks at recruitment * Able to communicate in Chinese and provide informed consent * Willing to participate in the study and complete follow-up assessments Exclusion Criteria: * Diagnosed epilepsy, photosensitive epilepsy, or other neurological disorders * Severe anxiety, depression, or other psychiatric disorders currently receiving intensive treatment * History of severe adverse reactions to virtual reality devices, including severe dizziness, nausea, or visual discomfort * Inability to participate in mindfulness or VR intervention proceduresriteria: Exclusion Criteria: \-
Conditions Breast Cancer
Phase NA
Enrollment 560
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Breast cancer is the most common cancer in women around the world. That means a lot of women are affected by it every year, and it's important that we always look for ways to improve their care, not just during treatment, but afterwards too. After treatment for early-stage breast cancer, patients usually come back to the hospital for regular check-ups for up to five years. These visits are based on old guidelines, and even though breast cancer treatment has improved a lot over the years, the follow-up schedule has stayed the same. This study is being done to see if we can safely reduce the number of hospital visits after treatment, while still keeping patients healthy and well looked after. Right now, patients are asked to attend follow-up appointments at 6, 12, 18, 24, 36, 48 and 60 months (that's every 6 to 12 months for five years). These clinic visits often involve long waits and can cause stress or anxiety. At the same time, patients are also invited for a mammogram once a year. Recent research shows that most recurrences of breast cancer are found by patients themselves or during their annual mammograms, not necessarily at these clinic visits. That's why we're looking at whether we can safely reduce the number of hospital appointments, without affecting patient safety. In this study, some patients will continue with the usual five-year clinic schedule. Others will only attend hospital clinics for the first two years (at 6, 12, 18 and 24 months), and after that, they will no longer need to come in for the extra follow-up visits, but they will still have their annual mammograms as normal. Within this study all participants will complete a short questionnaire once a year. This will help us understand how the different follow-up plans affect quality of life, and how patients feel about their care. This research study is taking place to find out if fewer hospital check-ups, combined with continued mammogram screening, is just as safe and possibly better for patients' wellbeing.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Other: De-Escalation of Management — Reduction in hospital based appointments to 2 years only and discharge to primary care for follow up post same.
  • Other: Control — Standard of care

Primary Outcomes

  • Health-Related Quality of Life Measured by the EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) (Measured at months 24, 36, 48 and 60 post randomisation.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-10-02
Completion: 2028-12-30
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 560 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Royal College of Surgeons, Ireland
Contact Information
Study Contact:
Prof Arnold Hill, MB, BCh, BAO, MCh, FRCSI
+35318093000
adkhill@rcsi.com
Aisling Hegarty, PhD
018093000
Aislinghegarty@rcsi.ie
Aisling Hegarty, PhD
018093000
Aislinghegarty@rcsi.ie
Beaumont RCSI Cancer Centre
Interventions
  • Other: De-Escalation of Management — Reduction in hospital based appointments to 2 years only and discharge to primary care for follow up post same.
  • Other: Control — Standard of care
Study Locations (1 sites)
Beaumont RCSI Cancer Centre, Beaumont, Dublin D09V2N0 Ireland
Eligibility Criteria
Inclusion Criteria: * Participants will be identified according to the eligibility criteria and will be approached and invited to participate in this study while attending the outpatient department at the breast centre in Beaumont Hospital. To be eligible to participate in this study, an individual must meet all of the following eligibility criteria: * Female patients who are under cancer surveillance for a primary breast cancer which was treated with curative intent * Aged 18 years or older at the time of 24-month surveillance * Demonstrate no clinical or radiological evidence of disease recurrence or metastases at the time of recruitment (e.g.: palpable mass, skin or nipple changes, new indeterminant mass on mammography, etc) * Fully fluent in English Language (Reading, Writing, and Speaking - has the ability to complete the EQ5D5L questionnaire in paper form and over the phone) * Has a formal address in the Republic of Ireland and has the intention of undergoing further surveillance in this country Exclusion Criteria: All individuals meeting any of the exclusion criteria at baseline or during screening will be excluded from study participation as per the following criteria: - An individual who fails to meet any of the aforementioned inclusion criteria will be excluded from participation in this study.